Immunization with IL-33 isoform plasmids enhances antigen-specific CD8+ T-cell responses, such as strong CD62L−KLRG1+ effector–memory CD8+ T-cell responses, which contribute to the suppression of tumor growth32. Here, CD8A is linked to neoplasm.